← Back

Jiangsu Sihuan Bioengineering Co Ltd

3.59+57.5%1Y · CNY

Jiangsu Sihuan Bioengineering Co., Ltd. produces and sells biopharmaceutical products in China and internationally. Its products include Delusen and New Delusen, a human interleukin-2 for injection used as an immunomodulator for tumor biotherapy and for patients with weakened immune function; Xinlisheng, a human granulocyte colony-stimulating factor injection for neutropenia caused by bone marrow transplantation, cancer chemotherapy, myelodysplastic syndrome, and aplastic anemia; and Huanerbo, a human erythropoietin injection for anemia caused by renal insufficiency. The company also engages in flower planting, forest and natural ecosystem management and protection, forest improvement, forestry product sales, Chinese herbal medicine planting, landscaping project construction, urban municipal greening management, scenic area management, municipal facilities management, earthwork construction, engineering management services, forest park management and design management, external contracting, project cost consulting services, and the sale of metal materials, agricultural and sideline products, and building and decoration materials. Founded in 1992, it is headquartered in Jiangyin, China.

Country
Price · split & dividend adjusted
News & notes moving 000518.CS
China
000518.CS▲2

Sihuan Bio to Acquire 80% Stake in Changyuan Pharmaceutical for 160 Million Yuan

Sihuan Bio announced that the company plans to acquire an 80% equity stake in Jilin Province Changyuan Pharmaceutical Co., Ltd. in cash, with a transaction price of 160 million yuan. Upon completion of this transaction, Changyuan Pharmaceutical will become a controlling subsidiary of Sihuan Bio. The target company's main products include succinylated gelatin injection and Naoshuankang capsules.
Jiangsu Sihuan… ▲
000518.CS · Capital · Positive Sihuan Bio plans to acquire an 80% stake in Changyuan Pharmaceutical for 160 million yuan, making it a controlling subsidiary.
Jilin Changyuan Pharmaceutical Co., Ltd. · Capital · Neutral Changyuan Pharmaceutical is the acquisition target, becoming a controlling subsidiary of Sihuan Bio.
Read original ↗
CLS·12dRead more →
China
000518.CS▼

Sihuan Bio's 2026 interim report shows net loss of 25.83 million yuan

Sihuan Bio has released its 2026 interim report, with net profit attributable to the parent company at a loss of 25.83 million yuan, an increase in loss of 15.73 million yuan compared with the same period last year. The company's total operating revenue was 111 million yuan, down 39.12 percent year on year, and net cash flow from operating activities was a negative 17.27 million yuan, down 134.43 percent year on year. The company's latest asset-liability ratio was 28.00 percent, gross margin was 20.57 percent, return on equity was negative 8.37 percent, and diluted earnings per share was negative 0.03 yuan.
Jiangsu Sihuan… ▼
000518.CS · Capital · Negative Net loss widened and revenue fell sharply in interim report
Read original ↗
Jiemian·45dRead more →
China
000518.CS▲2

Sihuan Bio to Acquire 80% Stake in Changyuan Pharmaceutical for 160 Million Yuan

Sihuan Bio announced that the company plans to acquire an 80% stake in Jilin Changyuan Pharmaceutical for 160 million yuan in cash. The target company is mainly engaged in the production and sale of pharmaceuticals, with its core product being succinylated gelatin injection. The transaction is still in the planning stage, and there is uncertainty as to whether it will ultimately be completed.
Jiangsu Sihuan… ▲
000518.CS · Capital · Positive Sihuan Bio plans to acquire 80% stake in Changyuan Pharmaceutical for 160 million yuan, expanding its portfolio.
Jilin Changyuan Pharmaceutical Co., Ltd. · Capital · Neutral Changyuan Pharmaceutical is the target of acquisition; impact depends on deal completion and terms.
Read original ↗
CLS·49dRead more →
© 2026 MarketDXAsset